Innovative Dual-Target Therapy for Obesity: Combining an oral GLP-1 Agonist with an oral Isoform Selective AMPK Activator`
Time: 2:40 pm
day: Day Two
Details:
- Mechanistic Synergy: BLX-7006, an oral GLP-1 agonist, promotes appetite suppression and glucose regulation, while BLX-0871, an oral isoform-selective AMPK activator, enhances skeletal muscle glucose uptake and lipid metabolism. Together, they address obesity through complementary pathways.
- Preclinical Evidence: Results from animal models demonstrate enhanced weight loss, improved insulin sensitivity, and significant metabolic improvements with the combined use of BLX-7006 and BLX-0871 compared to monotherapy.
- Future Clinical Potential: This dual-target strategy represents a next-generation approach to obesity treatment, offering the potential to overcome current therapeutic plateaus and address the underlying metabolic dysfunctions driving obesity
